General Information


DRAVP ID  DRAVPe02319

Peptide Name   EBOV-8

Sequence  IGIEDLSKNIKDKIDKIIHDFVDKTLPDQG

Sequence Length  30

UniProt ID  No entry found

Taxon ID  None

Source  Cholesterol-conjugated synthetic peptide

Validation   Experimentally Validated



Origin Information


Gene Name/ID  Not Available

GenBank  Not Available

Amino Acid position  Not Available

Domain Accession ID  Not Available

Nucleotide sequence ID  Not Available

Molecular Type  Not Available

Chromosomal Position  Not Available



Activity Information


Target Organism  EBOV

Assay  N/A

Activity 

  • [Ref:31473342]EBOV:EC50=18.47 plusminus 4.64 microM;EC90=69.49 microM.EBOV-GP EC50=4.02 plusminus 1.13 microM;EBOV-GP EC90=20.22 microM.ma-EBOV EC50=19.80 plusminus 1953 microM;ma-EBOV EC90=142 microM.GP =>GlycoProtein;ma =>Mouse-Adapted

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

  • [Ref:31473342]EBOV-8 show cytotoxicity (CC50) at greater than 30 microM.EBOV-5 show cytotoxicity (CC50) at >= 25 microM (when tested for EBOV-GP).EBOV-5 show cytotoxicity (CC50) at >= 44.0 microM (whe

Binding Target  Glycoprotein.

Mechanism  Exact MoA explicitly not available (EBOV-8 likely inhibits Ebola virus by targeting viral entry and fusion processes. It may interfere with viral glycoproteins, preventing the virus from attaching to and entering host cells. Additionally, EBOV-8 could disrupt the fusion between the viral envelope and host cell membrane, blocking the release of viral genetic material. By targeting these critical steps, the peptide effectively halts infection and viral replication. The specific antiviral mechanisms of EBOV-8 involve interactions with viral proteins essential for these processes. Detailed studies and assays in the full research paper would provide further insights into these mechanisms.).



Structure Information


PDB ID  None

Predicted Structure Download 

Linear/Cyclic  Cyclic

N-terminal Modification  cholesterylation

C-terminal Modification  PEG12

Other Modification  In the peptide sequence, the cysteine residue at position 31 is modified with a PEG12-cholesterol (PEG12-Chol) moiety

Stereochemistry  L



Physicochemical Information


Formula  C152H251N39O49

Absent amino acids  ACMORUWY

Common amino acids  DI

Mass  3408.9

Pl  4.89

Basic residues  5

Acidic residues  7

Hydrophobic residues  10

Net charge  -2

Boman Index  2.04

Hydrophobicity  -0.55

Aliphatic Index  113.67

Half Life 

  •     Mammalian:20hours
  •     Yeast:30min
  •     E.coli:>10hours

Extinction Coefficient cystines  None

Absorbance 280nm  None

Polar residues  17



Literature Information


Literature 1

Title   Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo

Pubmed ID   31473342

Reference   Antiviral Res. 2019;171:104592. 

Author   Pessi A, Bixler SL, Soloveva V, et al

DOI   10.1016/j.antiviral.2019.104592